Work

The effects of tungsten inhalation and continuous administration of angiotensin II on cardiac injury and pulmonary outcomes

Year: 2026

Type: article

Abstract: Tungsten exposure is associated with multiple cardiovascular diseases, but limited information exists on the mechanistic underpinnings of these relationships. The current study investigated the individual and combined effects of angiotensin II (AT-II) treatment, as a model of accelerated cardiovascular disease risk, and tungsten (W) exposure on cardiac function, to provide insights into potential mechanisms involved in tungsten-mediated cardiac injury. Mice received AT-II (0.73 mg/kg/d) or saline (Veh) for 24 days through osmotic mini-pumps. The final 2-weeks of treatment, mice were exposed 4 times (4 h each) to filtered air (FA) or 1.50 ± 0.22 mg/m 3 W particles by whole-body inhalation. Laser ablation and bulk inductively-coupled plasma mass spectrometry (ICP-MS) of lung samples indicated an accumulation of iron in AT-II treatment groups and confirmed the deposition of W and decreases in essential elements zinc, magnesium, and molybdenum in exposure groups. Echocardiographic data showed W exposure decreased cardiac output and stroke volume; however treatment with AT-II did not further exacerbate W's effects. The A'/E' ratio was significantly elevated in the AT-II + W group compared to the W + Veh group and trending significant compared to the FA + AT-II group. Blood cardiac troponin I was elevated in the W + AT-II group compared to either FA + Veh or W + Veh groups. Results suggest an interactive effect of both W and AT-II to drive cardiac injury following exposure. However, neither W exposure nor AT-II treatment resulted in pulmonary inflammation at the terminal endpoint of the study. Data illustrate pathophysiological effects of inhaled W and AT-II that contribute to cardiac injury. • Inhalation exposure to tungsten particulates decreased concentrations of essential elements zinc, magnesium, and molybdenum in the lungs. • Inhalation exposure to tungsten particulates and treatment with angiotensin II does not lead to sustained pulmonary inflammation. • Inhalation exposure to tungsten particulates led to decreased cardiac output and stroke volume in the heart, however angiotensin II treatment did not further exacerbate these effects. • Inhalation exposure to tungsten particulates and angiotensin II treatment interact to drive cardiac injury (increased A'/E' ratio and cardiac troponin I level).

Source: Toxicology and Applied Pharmacology

DOI: 10.1016/j.taap.2026.117753